PapersFlow Research Brief
Virus-based gene therapy research
Research Guide
What is Virus-based gene therapy research?
Virus-based gene therapy research is the study and development of therapeutic strategies that use engineered viruses as vectors to deliver genetic material into human cells to alter gene expression or cellular function for disease treatment.
Virus-based gene therapy research spans viral vector design (e.g., adenovirus-associated systems), methods to control transgene expression, and evaluation of safety issues such as genomic integration and immune responses.
Topic Hierarchy
Research Sub-Topics
Adeno-Associated Virus Vectors for Gene Therapy
Researchers engineer AAV serotypes for tissue tropism, capsid modification, and high-titer production to deliver transgenes safely. Clinical applications target retinal, neuromuscular, and liver diseases with durable expression.
Lentiviral Vectors in Hematopoietic Stem Cell Therapy
This field optimizes SIN lentiviral backbones for stable integration and expression in HSCs treating immunodeficiencies and hemoglobinopathies. Genotoxicity studies guide insulator and promoter refinements.
Oncolytic Virus Therapy for Cancer
Studies engineer herpes, adenovirus, and reovirus for tumor-selective replication, immune checkpoint modulation, and combination with checkpoint inhibitors. Phase III trials evaluate survival endpoints in melanoma and glioma.
Genomic Integration Safety of Viral Vectors
Researchers profile integration site preferences using LAM-PCR and NGS to assess insertional mutagenesis risks in retro/lentiviral therapies. Risk models predict oncogene hits from clonal tracking.
Transgene Expression Optimization in Viral Vectors
This sub-topic designs codon-optimized cDNAs, synthetic promoters, and miRNA detargeting for physiological expression levels and immune evasion. Dose-response studies correlate vector genomes to therapeutic efficacy.
Why It Matters
Virus-based gene therapy research matters because viral vectors are a practical route to delivering genetic payloads into cells at clinically meaningful levels, enabling therapies that are difficult to achieve with conventional drugs. A clear example of real-world impact is engineered T-cell therapy, where gene transfer is used to create chimeric antigen receptor (CAR) T cells for leukemia: Maude et al. (2014) in "Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia" reported CD19-directed CAR T-cell activity with durable remissions up to 24 months in relapsed/refractory acute lymphoblastic leukemia (ALL), and Maude et al. (2018) in "Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia" reported durable remission with long-term persistence after a single infusion in pediatric and young adult patients with relapsed/refractory B-cell ALL, alongside transient high-grade toxic effects. These studies illustrate how virus-enabled gene delivery can reprogram patient-derived cells into living therapeutics, shifting treatment options in hematologic malignancies from repeated cytotoxic regimens toward single-administration cellular products with measurable persistence.
Reading Guide
Where to Start
Start with "A new technique for the assay of infectivity of human adenovirus 5 DNA" (1973) because it illustrates how viral DNA function can be measured experimentally, a foundational concept for evaluating viral vectors and their genomes.
Key Papers Explained
Methodological foundations for gene delivery and expression measurement connect several highly cited works. Graham and van der Eb’s "A new technique for the assay of infectivity of human adenovirus 5 DNA" (1973) supports thinking about how vector genomes can be tested for functional activity, while Dignam et al.’s "Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei" (1983) links viral promoters (adenovirus 2 major late promoter) to mechanistic control of transcription initiation. For practical gene transfer and benchmarking, Chen and Okayama’s "High-efficiency transformation of mammalian cells by plasmid DNA." (1987) and Boussif et al.’s "A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine." (1995) provide non-viral transfer methods often used to prototype constructs before viral packaging. Niwa et al.’s "Efficient selection for high-expression transfectants with a novel eukaryotic vector" (1991) adds selection logic that complements viral-vector goals of durable expression. These enabling methods connect to clinical gene-modified cell therapy outcomes in Maude et al.’s "Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia" (2014) and "Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia" (2018), which show how gene transfer can yield persistent therapeutic cells and durable remissions in ALL.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
An advanced reading path is to treat the clinical CAR T-cell studies—"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia" (2014) and "Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia" (2018)—as constraints that motivate upstream vector and expression-system design. From there, revisit "Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei" (1983) and "Efficient selection for high-expression transfectants with a novel eukaryotic vector" (1991) to frame research questions about expression predictability, potency, and persistence under clinically relevant manufacturing and dosing scenarios.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Accurate transcription initiation by RNA polymerase II in a so... | 1983 | Nucleic Acids Research | 11.6K | ✓ |
| 2 | A new technique for the assay of infectivity of human adenovir... | 1973 | Virology | 9.7K | ✕ |
| 3 | Duplexes of 21-nucleotide RNAs mediate RNA interference in cul... | 2001 | Nature | 9.3K | ✕ |
| 4 | The serial cultivation of human diploid cell strains | 1961 | Experimental Cell Rese... | 8.3K | ✕ |
| 5 | A versatile vector for gene and oligonucleotide transfer into ... | 1995 | Proceedings of the Nat... | 6.2K | ✓ |
| 6 | [2] New M13 vectors for cloning | 1983 | Methods in enzymology ... | 5.4K | ✕ |
| 7 | High-efficiency transformation of mammalian cells by plasmid DNA. | 1987 | Molecular and Cellular... | 5.3K | ✓ |
| 8 | Tisagenlecleucel in Children and Young Adults with B-Cell Lymp... | 2018 | New England Journal of... | 5.3K | ✓ |
| 9 | Chimeric Antigen Receptor T Cells for Sustained Remissions in ... | 2014 | New England Journal of... | 5.2K | ✓ |
| 10 | Efficient selection for high-expression transfectants with a n... | 1991 | Gene | 5.2K | ✕ |
In the News
Genetic engineering of systemically injectable oncolytic viruses for pyroptosis-accelerated cancer virotherapy
Systemic delivery of oncolytic viruses (OVs) is limited by neutralizing antibodies and poor intratumoral bioavailability. Here we developed genetically engineered, immune-compatible cell membranes ...
Ultra-rare Gene-based Therapy (URGenT) Network
(ALS)|Antisense Oligonucleotides (ASOs)|
Taysha Gene Therapies Announces FDA Breakthrough ...
Taysha Gene Therapies(Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central ner...
Lentiviral Vector Improves Gene Therapy for Neurological ...
**An approved gene therapy has been modified with a new lentiviral vector, demonstrating improved safety and expanding the eligibility criteria.**
Latest News
Please wait while your request is being verified...
Code & Tools
reproducible-research glue open-science comparative-genomics aav gene-therapy virus-evolution paleovirology parvovirus
## Repository files navigation # EngrAAV #### An AI-based tool to design AAV-capsids optimized for production cost.
The **Retrovirus Database (RVdb)** is a ** GLUE ** resource supporting comparative analysis of retroviruses (family _Retroviridae_). RVdb was creat...
Appearance settings Search or jump to... # Search code, repositories, users, issues, pull requests... Search Clear Search syntax tips # Provide...
VIRULIGN is an easy-to-use command line application to construct codon-correct alignments of large virus sequence datasets. Additionally, VIRULIGN ...
Recent Preprints
Advances in β-Thalassemia Gene Therapy: CRISPR/Cas ...
delivery remains a major challenge. Viral vectors offer high efficiency but raise concerns about immunogenicity and insertional mutagenesis, whereas non-viral systems such as lipid nanoparticles an...
AAV gene therapy rescues hearing and balance in a model of ...
Adeno-associated virus-based gene therapy offers a promising treatment paradigm for inner ear diseases; however, the genetic heterogeneity of hereditary deafness requires gene-specific strategies a...
Adeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy - PubMed
Gene therapy offers promising potential as an efficacious and long-lasting therapeutic option for genetic conditions, by correcting defective mutations using engineered vectors to deliver genetic m...
Viral and non-viral vectors in gene therapy: current state ...
Advancements in gene therapy have achieved significant milestones in treating human diseases, offering renewed hope to patients with limited options. Key to this progress are vectors, which include...
Cell and Gene Therapy: Transforming Treatment ...
patient‐centered perspectives. Key topics on gene therapy included “platformization” to streamline development, lessons from adeno‐associated virus‐based gene therapies for hemophilia from patient ...
Latest Developments
Recent developments in virus-based gene therapy research include advancements in CRISPR/Cas9-based virology research and in vivo genome editing using rAAV vectors, with notable progress in improving delivery methods and addressing challenges in therapeutic applications as of early 2026 (PMC, Nature).
Sources
Frequently Asked Questions
What is virus-based gene therapy research?
Virus-based gene therapy research studies how engineered viruses can be used as delivery vehicles to introduce therapeutic genetic material into cells to change gene expression or cell behavior for treatment. The work includes vector construction, manufacturing methods, and biological evaluation of expression, persistence, and safety outcomes.
How are adenoviruses used as tools in gene therapy research and vector development?
Adenoviruses have served as model systems for optimizing gene expression control and for developing assays and methods that support viral DNA handling and delivery. Dignam et al. (1983) in "Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei" optimized in vitro transcription conditions using the major late promoter of adenovirus 2, and Graham and van der Eb (1973) in "A new technique for the assay of infectivity of human adenovirus 5 DNA" described a technique to assay infectivity of adenovirus 5 DNA.
Which experimental methods underpin evaluation of transgene expression in mammalian cells?
Core methods include reliable mammalian cell culture and high-efficiency gene transfer protocols that allow controlled comparisons of constructs and promoters. Hayflick and Moorhead (1961) in "The serial cultivation of human diploid cell strains" established widely used diploid cell culture approaches, while Chen and Okayama (1987) in "High-efficiency transformation of mammalian cells by plasmid DNA." described a calcium phosphate method for efficient mammalian cell transformation that supports rapid testing of expression cassettes.
How do researchers select for cells with strong expression of an introduced gene?
Selection systems and vector designs are used to enrich for cells that maintain high expression after gene transfer. Niwa et al. (1991) in "Efficient selection for high-expression transfectants with a novel eukaryotic vector" described a strategy for selecting high-expression transfectants, which is directly relevant to building and benchmarking expression systems used alongside viral-vector work.
Which non-viral delivery tools are commonly compared against viral vectors in gene therapy studies?
Non-viral transfection reagents and protocols are frequently used as comparators for delivery efficiency, expression levels, and toxicity in vitro and sometimes in vivo. Boussif et al. (1995) in "A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine." reported polyethylenimine as a transfer agent for genes and oligonucleotides, and Chen and Okayama (1987) in "High-efficiency transformation of mammalian cells by plasmid DNA." provided a widely used calcium phosphate approach for introducing DNA into mammalian cells.
How does virus-based gene transfer relate to clinically used CAR T-cell therapies for leukemia?
CAR T-cell therapies are enabled by gene transfer that introduces chimeric antigen receptor constructs into patient-derived T cells, producing cells with new antigen specificity and effector function. Maude et al. (2014) in "Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia" and Maude et al. (2018) in "Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia" provide clinical evidence that gene-modified T cells can induce remissions and persist long-term after a single infusion in relapsed/refractory ALL.
Open Research Questions
- ? How can viral-vector expression cassettes be engineered to achieve predictable, promoter-accurate transcription initiation across target cell types, building on the promoter and transcription-initiation principles studied in "Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei" (1983)?
- ? Which experimental assays best predict functional delivery and biological activity of viral DNA or vector genomes in clinically relevant settings, extending concepts from "A new technique for the assay of infectivity of human adenovirus 5 DNA" (1973)?
- ? What design choices in gene-transfer constructs and selection strategies most strongly determine long-term high expression after integration or persistence, informed by "Efficient selection for high-expression transfectants with a novel eukaryotic vector" (1991)?
- ? How can gene-transfer approaches be optimized to maximize therapeutic persistence while limiting severe transient toxicities observed in clinical gene-modified cell therapies, as described in "Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia" (2018)?
- ? Which manufacturing and cell-processing variables most affect the durability of remissions and persistence of engineered T cells, as reported in "Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia" (2014)?
Recent Trends
Across the provided highly cited literature, the most visible application trend is the maturation of gene-modified cell therapies into large, clinically impactful studies in leukemia.
Maude et al. in "Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia" reported durable remissions up to 24 months, and Maude et al. (2018) in "Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia" reported durable remission with long-term persistence after a single infusion while also documenting transient high-grade toxic effects.
2014In parallel, the field continues to rely on a methodological backbone of reproducible gene transfer and expression measurement—e.g., promoter-accurate transcription assays using an adenovirus promoter in "Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei" and practical high-efficiency DNA delivery methods in "High-efficiency transformation of mammalian cells by plasmid DNA." (1987)—to iteratively improve vector constructs and evaluate expression outcomes.
1983Research Virus-based gene therapy research with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Virus-based gene therapy research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers